ID   GTR9_HUMAN              Reviewed;         540 AA.
AC   Q9NRM0; Q0VGC4; Q4W5D1; Q8WV30; Q96P00;
DT   16-NOV-2001, integrated into UniProtKB/Swiss-Prot.
DT   13-JUL-2010, sequence version 2.
DT   10-MAY-2017, entry version 143.
DE   RecName: Full=Solute carrier family 2, facilitated glucose transporter member 9;
DE   AltName: Full=Glucose transporter type 9;
DE            Short=GLUT-9;
GN   Name=SLC2A9; Synonyms=GLUT9;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ARG-25 AND
RP   LEU-350.
RC   TISSUE=Kidney;
RX   PubMed=10860667; DOI=10.1006/geno.2000.6195;
RA   Phay J.E., Hussain H.B., Moley J.F.;
RT   "Cloning and expression analysis of a novel member of the facilitative
RT   glucose transporter family, SLC2A9 (GLUT9).";
RL   Genomics 66:217-220(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND
RP   VARIANTS ARG-25 AND LEU-350.
RC   TISSUE=Lung, and Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 85-238 (ISOFORM 1), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Articular cartilage;
RX   PubMed=11991658; DOI=10.1006/cbir.2001.0850;
RA   Mobasheri A., Neama G., Bell S., Richardson S., Carter S.D.;
RT   "Human articular chondrocytes express three facilitative glucose
RT   transporter isoforms: GLUT1, GLUT3 and GLUT9.";
RL   Cell Biol. Int. 26:297-300(2002).
RN   [5]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY (ISOFORMS 1 AND
RP   2).
RX   PubMed=14739288; DOI=10.1074/jbc.M312226200;
RA   Augustin R., Carayannopoulos M.O., Dowd L.O., Phay J.E., Moley J.F.,
RA   Moley K.H.;
RT   "Identification and characterization of human glucose transporter-like
RT   protein-9 (GLUT9): alternative splicing alters trafficking.";
RL   J. Biol. Chem. 279:16229-16236(2004).
RN   [6]
RP   INVOLVEMENT IN THE REGULATION OF SERUM URIC ACID CONCENTRATION, AND
RP   VARIANTS ASP-191; HIS-281; ILE-282 AND LEU-350.
RX   PubMed=18327256; DOI=10.1038/ng.107;
RA   Doering A., Gieger C., Mehta D., Gohlke H., Prokisch H., Coassin S.,
RA   Fischer G., Henke K., Klopp N., Kronenberg F., Paulweber B.,
RA   Pfeufer A., Rosskopf D., Voelzke H., Illig T., Meitinger T.,
RA   Wichmann H.-E., Meisinger C.;
RT   "SLC2A9 influences uric acid concentrations with pronounced sex-
RT   specific effects.";
RL   Nat. Genet. 40:430-436(2008).
RN   [7]
RP   INVOLVEMENT IN THE REGULATION OF SERUM URIC ACID CONCENTRATION,
RP   FUNCTION, AND VARIANTS ASN-22; ARG-216; MET-275; HIS-281 AND HIS-300.
RX   PubMed=18327257; DOI=10.1038/ng.106;
RA   Vitart V., Rudan I., Hayward C., Gray N.K., Floyd J., Palmer C.N.,
RA   Knott S.A., Kolcic I., Polasek O., Graessler J., Wilson J.F.,
RA   Marinaki A., Riches P.L., Shu X., Janicijevic B., Smolej-Narancic N.,
RA   Gorgoni B., Morgan J., Campbell S., Biloglav Z., Barac-Lauc L.,
RA   Pericic M., Klaric I.M., Zgaga L., Skaric-Juric T., Wild S.H.,
RA   Richardson W.A., Hohenstein P., Kimber C.H., Tenesa A., Donnelly L.A.,
RA   Fairbanks L.D., Aringer M., McKeigue P.M., Ralston S.H., Morris A.D.,
RA   Rudan P., Hastie N.D., Campbell H., Wright A.F.;
RT   "SLC2A9 is a newly identified urate transporter influencing serum
RT   urate concentration, urate excretion and gout.";
RL   Nat. Genet. 40:437-442(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-9 AND SER-515, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [9]
RP   SUBCELLULAR LOCATION (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY.
RX   PubMed=24409316; DOI=10.1371/journal.pone.0084996;
RA   Kimura T., Takahashi M., Yan K., Sakurai H.;
RT   "Expression of SLC2A9 isoforms in the kidney and their localization in
RT   polarized epithelial cells.";
RL   PLoS ONE 9:E84996-E84996(2014).
RN   [10]
RP   VARIANTS RHUC2 CYS-198 AND TRP-380, AND CHARACTERIZATION OF VARIANTS
RP   RHUC2 CYS-198 AND TRP-380.
RX   PubMed=19026395; DOI=10.1016/j.ajhg.2008.11.001;
RA   Matsuo H., Chiba T., Nagamori S., Nakayama A., Domoto H., Phetdee K.,
RA   Wiriyasermkul P., Kikuchi Y., Oda T., Nishiyama J., Nakamura T.,
RA   Morimoto Y., Kamakura K., Sakurai Y., Nonoyama S., Kanai Y.,
RA   Shinomiya N.;
RT   "Mutations in glucose transporter 9 gene SLC2A9 cause renal
RT   hypouricemia.";
RL   Am. J. Hum. Genet. 83:744-751(2008).
RN   [11]
RP   ERRATUM.
RA   Matsuo H., Chiba T., Nagamori S., Nakayama A., Domoto H., Phetdee K.,
RA   Wiriyasermkul P., Kikuchi Y., Oda T., Nishiyama J., Nakamura T.,
RA   Morimoto Y., Kamakura K., Sakurai Y., Nonoyama S., Kanai Y.,
RA   Shinomiya N.;
RL   Am. J. Hum. Genet. 83:795-795(2008).
RN   [12]
RP   VARIANT RHUC2 ARG-75, AND CHARACTERIZATION OF VARIANT RHUC2 ARG-75.
RX   PubMed=19926891; DOI=10.1681/ASN.2009040406;
RA   Dinour D., Gray N.K., Campbell S., Shu X., Sawyer L., Richardson W.,
RA   Rechavi G., Amariglio N., Ganon L., Sela B.A., Bahat H., Goldman M.,
RA   Weissgarten J., Millar M.R., Wright A.F., Holtzman E.J.;
RT   "Homozygous SLC2A9 mutations cause severe renal hypouricemia.";
RL   J. Am. Soc. Nephrol. 21:64-72(2010).
RN   [13]
RP   VARIANTS RHUC2 MET-125 AND CYS-171, AND CHARACTERIZATION OF VARIANTS
RP   RHUC2 MET-125 AND CYS-171.
RX   PubMed=21810765; DOI=10.1093/ndt/gfr419;
RA   Dinour D., Gray N.K., Ganon L., Knox A.J., Shalev H., Sela B.A.,
RA   Campbell S., Sawyer L., Shu X., Valsamidou E., Landau D., Wright A.F.,
RA   Holtzman E.J.;
RT   "Two novel homozygous SLC2A9 mutations cause renal hypouricemia type
RT   2.";
RL   Nephrol. Dial. Transplant. 27:1035-1041(2012).
RN   [14]
RP   CHARACTERIZATION OF VARIANTS ARG-25; MET-169; MET-275; HIS-281;
RP   ILE-282; HIS-294 AND LEU-350.
RX   PubMed=25268603; DOI=10.1371/journal.pone.0107902;
RA   Hurba O., Mancikova A., Krylov V., Pavlikova M., Pavelka K.,
RA   Stiburkova B.;
RT   "Complex analysis of urate transporters SLC2A9, SLC22A12 and
RT   functional characterization of non-synonymous allelic variants of
RT   GLUT9 in the Czech population: no evidence of effect on hyperuricemia
RT   and gout.";
RL   PLoS ONE 9:E107902-E107902(2014).
CC   -!- FUNCTION: Transport urate and fructose. May have a role in the
CC       urate reabsorption by proximal tubules. Also transports glucose at
CC       low rate. {ECO:0000269|PubMed:14739288,
CC       ECO:0000269|PubMed:18327257}.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Basolateral cell membrane
CC       {ECO:0000269|PubMed:14739288, ECO:0000269|PubMed:24409316}; Multi-
CC       pass membrane protein {ECO:0000269|PubMed:14739288}.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Apical cell membrane
CC       {ECO:0000269|PubMed:24409316}; Multi-pass membrane protein.
CC       Basolateral cell membrane {ECO:0000269|PubMed:14739288,
CC       ECO:0000269|PubMed:24409316}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:14739288}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=SLC2A9-L;
CC         IsoId=Q9NRM0-1; Sequence=Displayed;
CC       Name=2; Synonyms=GLUT9deltaN, SLC2A9-S;
CC         IsoId=Q9NRM0-2; Sequence=VSP_034860;
CC         Note=Variant in position: 17:A->T (in dbSNP:6820230).;
CC   -!- TISSUE SPECIFICITY: Most strongly expressed in basolateral
CC       membranes of proximal renal tubular cells, liver and placenta.
CC       Also detected in lung, blood leukocytes, heart skeletal muscle and
CC       chondrocytes from articular cartilage. Isoform 2 is only detected
CC       in the apical membranes of polarized renal tubular cells and
CC       placenta. Isoform 1 and isoform 2 are detected in kidney membrane
CC       (at protein level). {ECO:0000269|PubMed:11991658,
CC       ECO:0000269|PubMed:24409316}.
CC   -!- POLYMORPHISM: Genetic variations in SLC2A9 influence the variance
CC       in serum uric acid concentrations and define the serum uric acid
CC       concentration quantitative trait locus 2 (UAQTL2) [MIM:612076].
CC       Excess serum accumulation of uric acid can lead to the development
CC       of gout.
CC   -!- DISEASE: Hypouricemia renal 2 (RHUC2) [MIM:612076]: A disorder
CC       characterized by impaired uric acid reabsorption at the apical
CC       membrane of proximal renal tubule cells, and high urinary urate
CC       excretion. Patients often appear asymptomatic, but may be subject
CC       to exercise-induced acute renal failure, chronic renal dysfunction
CC       and nephrolithiasis. {ECO:0000269|PubMed:19026395,
CC       ECO:0000269|PubMed:19926891, ECO:0000269|PubMed:21810765}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the major facilitator superfamily. Sugar
CC       transporter (TC 2.A.1.1) family. Glucose transporter subfamily.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF210317; AAF85942.1; -; mRNA.
DR   EMBL; AC005674; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC098976; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC108199; AAY41052.1; -; Genomic_DNA.
DR   EMBL; BC018897; AAH18897.1; -; mRNA.
DR   EMBL; BC110414; AAI10415.1; -; mRNA.
DR   EMBL; AF421859; AAL16939.1; -; mRNA.
DR   CCDS; CCDS3406.1; -. [Q9NRM0-2]
DR   CCDS; CCDS3407.1; -. [Q9NRM0-1]
DR   RefSeq; NP_001001290.1; NM_001001290.1. [Q9NRM0-2]
DR   RefSeq; NP_064425.2; NM_020041.2. [Q9NRM0-1]
DR   UniGene; Hs.444612; -.
DR   UniGene; Hs.656895; -.
DR   ProteinModelPortal; Q9NRM0; -.
DR   BioGrid; 121156; 1.
DR   STRING; 9606.ENSP00000264784; -.
DR   ChEMBL; CHEMBL2052034; -.
DR   DrugBank; DB00678; Losartan.
DR   DrugBank; DB01032; Probenecid.
DR   DrugBank; DB08844; Uric Acid.
DR   TCDB; 2.A.1.1.72; the major facilitator superfamily (mfs).
DR   iPTMnet; Q9NRM0; -.
DR   PhosphoSitePlus; Q9NRM0; -.
DR   BioMuta; SLC2A9; -.
DR   DMDM; 300669647; -.
DR   PaxDb; Q9NRM0; -.
DR   PeptideAtlas; Q9NRM0; -.
DR   PRIDE; Q9NRM0; -.
DR   DNASU; 56606; -.
DR   Ensembl; ENST00000264784; ENSP00000264784; ENSG00000109667. [Q9NRM0-1]
DR   Ensembl; ENST00000309065; ENSP00000311383; ENSG00000109667. [Q9NRM0-2]
DR   Ensembl; ENST00000506583; ENSP00000422209; ENSG00000109667. [Q9NRM0-2]
DR   GeneID; 56606; -.
DR   KEGG; hsa:56606; -.
DR   UCSC; uc003gmc.4; human. [Q9NRM0-1]
DR   CTD; 56606; -.
DR   DisGeNET; 56606; -.
DR   GeneCards; SLC2A9; -.
DR   H-InvDB; HIX0004090; -.
DR   HGNC; HGNC:13446; SLC2A9.
DR   HPA; HPA066229; -.
DR   MalaCards; SLC2A9; -.
DR   MIM; 606142; gene.
DR   MIM; 612076; phenotype.
DR   neXtProt; NX_Q9NRM0; -.
DR   OpenTargets; ENSG00000109667; -.
DR   Orphanet; 94088; Hereditary renal hypouricemia.
DR   PharmGKB; PA37771; -.
DR   eggNOG; KOG0569; Eukaryota.
DR   eggNOG; COG0477; LUCA.
DR   GeneTree; ENSGT00760000119022; -.
DR   HOGENOM; HOG000202871; -.
DR   HOVERGEN; HBG014816; -.
DR   InParanoid; Q9NRM0; -.
DR   KO; K08146; -.
DR   OMA; VFATICI; -.
DR   OrthoDB; EOG091G0A9K; -.
DR   PhylomeDB; Q9NRM0; -.
DR   TreeFam; TF313762; -.
DR   Reactome; R-HSA-428776; Class II GLUTs.
DR   GeneWiki; SLC2A9; -.
DR   GenomeRNAi; 56606; -.
DR   PRO; PR:Q9NRM0; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000109667; -.
DR   CleanEx; HS_SLC2A9; -.
DR   ExpressionAtlas; Q9NRM0; baseline and differential.
DR   Genevisible; Q9NRM0; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005355; F:glucose transmembrane transporter activity; IEA:Ensembl.
DR   GO; GO:0005351; F:sugar:proton symporter activity; NAS:UniProtKB.
DR   GO; GO:0022857; F:transmembrane transporter activity; TAS:Reactome.
DR   GO; GO:0015143; F:urate transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0015758; P:glucose transport; NAS:UniProtKB.
DR   GO; GO:0046415; P:urate metabolic process; IMP:UniProtKB.
DR   CDD; cd06174; MFS; 1.
DR   InterPro; IPR020846; MFS_dom.
DR   InterPro; IPR005828; MFS_sugar_transport-like.
DR   InterPro; IPR003663; Sugar/inositol_transpt.
DR   InterPro; IPR005829; Sugar_transporter_CS.
DR   Pfam; PF00083; Sugar_tr; 1.
DR   PRINTS; PR00171; SUGRTRNSPORT.
DR   SUPFAM; SSF103473; SSF103473; 2.
DR   TIGRFAMs; TIGR00879; SP; 1.
DR   PROSITE; PS50850; MFS; 1.
DR   PROSITE; PS00216; SUGAR_TRANSPORT_1; 1.
DR   PROSITE; PS00217; SUGAR_TRANSPORT_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Complete proteome;
KW   Disease mutation; Glycoprotein; Membrane; Phosphoprotein;
KW   Polymorphism; Reference proteome; Sugar transport; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN         1    540       Solute carrier family 2, facilitated
FT                                glucose transporter member 9.
FT                                /FTId=PRO_0000050378.
FT   TOPO_DOM      1     51       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     52     72       Helical; Name=1. {ECO:0000255}.
FT   TOPO_DOM     73    107       Extracellular. {ECO:0000255}.
FT   TRANSMEM    108    128       Helical; Name=2. {ECO:0000255}.
FT   TOPO_DOM    129    140       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    141    161       Helical; Name=3. {ECO:0000255}.
FT   TOPO_DOM    162    171       Extracellular. {ECO:0000255}.
FT   TRANSMEM    172    192       Helical; Name=4. {ECO:0000255}.
FT   TOPO_DOM    193    200       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    201    221       Helical; Name=5. {ECO:0000255}.
FT   TOPO_DOM    222    231       Extracellular. {ECO:0000255}.
FT   TRANSMEM    232    252       Helical; Name=6. {ECO:0000255}.
FT   TOPO_DOM    253    316       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    317    337       Helical; Name=7. {ECO:0000255}.
FT   TOPO_DOM    338    354       Extracellular. {ECO:0000255}.
FT   TRANSMEM    355    375       Helical; Name=8. {ECO:0000255}.
FT   TOPO_DOM    376    381       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    382    402       Helical; Name=9. {ECO:0000255}.
FT   TOPO_DOM    403    415       Extracellular. {ECO:0000255}.
FT   TRANSMEM    416    436       Helical; Name=10. {ECO:0000255}.
FT   TOPO_DOM    437    451       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    452    472       Helical; Name=11. {ECO:0000255}.
FT   TOPO_DOM    473    478       Extracellular. {ECO:0000255}.
FT   TRANSMEM    479    499       Helical; Name=12. {ECO:0000255}.
FT   TOPO_DOM    500    540       Cytoplasmic. {ECO:0000255}.
FT   REGION      327    333       Monosaccharide binding. {ECO:0000250}.
FT   MOD_RES       9      9       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     515    515       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   CARBOHYD     90     90       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ       1     50       MARKQNRNSKELGLVPLTDDTSHAGPPGPGRALLECDHLRS
FT                                GVPGGRRRK -> MKLSKKDRGEDEESDSAKKKL (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_034860.
FT   VARIANT      22     22       S -> N. {ECO:0000269|PubMed:18327257}.
FT                                /FTId=VAR_045648.
FT   VARIANT      25     25       G -> R (polymorphism; no effect on urate
FT                                transport activity; dbSNP:rs2276961).
FT                                {ECO:0000269|PubMed:10860667,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:25268603}.
FT                                /FTId=VAR_012157.
FT   VARIANT      75     75       L -> R (in RHUC2; reduced urate transport
FT                                activity; dbSNP:rs863225072).
FT                                {ECO:0000269|PubMed:19926891}.
FT                                /FTId=VAR_065772.
FT   VARIANT     125    125       T -> M (in RHUC2; markedly reduced urate
FT                                transport activity; dbSNP:rs181509591).
FT                                {ECO:0000269|PubMed:21810765}.
FT                                /FTId=VAR_065773.
FT   VARIANT     169    169       V -> M (polymorphism; no effect on urate
FT                                transport activity; dbSNP:rs144196049).
FT                                {ECO:0000269|PubMed:25268603}.
FT                                /FTId=VAR_075343.
FT   VARIANT     171    171       R -> C (in RHUC2; markedly reduced urate
FT                                transport activity; dbSNP:rs776127501).
FT                                {ECO:0000269|PubMed:21810765}.
FT                                /FTId=VAR_065774.
FT   VARIANT     191    191       E -> D (in dbSNP:rs376990050).
FT                                {ECO:0000269|PubMed:18327256}.
FT                                /FTId=VAR_045649.
FT   VARIANT     198    198       R -> C (in RHUC2; markedly reduced urate
FT                                transport activity; dbSNP:rs121908322).
FT                                {ECO:0000269|PubMed:19026395}.
FT                                /FTId=VAR_065775.
FT   VARIANT     216    216       G -> R (in dbSNP:rs561633150).
FT                                {ECO:0000269|PubMed:18327257}.
FT                                /FTId=VAR_045650.
FT   VARIANT     275    275       T -> M (polymorphism; no effect on urate
FT                                transport activity; dbSNP:rs112404957).
FT                                {ECO:0000269|PubMed:18327257,
FT                                ECO:0000269|PubMed:25268603}.
FT                                /FTId=VAR_045651.
FT   VARIANT     281    281       D -> H (polymorphism; no effect on urate
FT                                transport activity; dbSNP:rs73225891).
FT                                {ECO:0000269|PubMed:18327256,
FT                                ECO:0000269|PubMed:18327257,
FT                                ECO:0000269|PubMed:25268603}.
FT                                /FTId=VAR_045652.
FT   VARIANT     282    282       V -> I (polymorphism; no effect on urate
FT                                transport activity; dbSNP:rs16890979).
FT                                {ECO:0000269|PubMed:18327256,
FT                                ECO:0000269|PubMed:25268603}.
FT                                /FTId=VAR_012158.
FT   VARIANT     294    294       R -> H (polymorphism; no effect on urate
FT                                transport activity; dbSNP:rs3733591).
FT                                {ECO:0000269|PubMed:25268603}.
FT                                /FTId=VAR_020337.
FT   VARIANT     300    300       R -> H (in dbSNP:rs145688560).
FT                                {ECO:0000269|PubMed:18327257}.
FT                                /FTId=VAR_045653.
FT   VARIANT     350    350       P -> L (polymorphism; no effect on urate
FT                                transport activity; dbSNP:rs2280205).
FT                                {ECO:0000269|PubMed:10860667,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:18327256,
FT                                ECO:0000269|PubMed:25268603}.
FT                                /FTId=VAR_012159.
FT   VARIANT     380    380       R -> W (in RHUC2; markedly reduced urate
FT                                transport activity; dbSNP:rs121908321).
FT                                {ECO:0000269|PubMed:19026395}.
FT                                /FTId=VAR_065776.
SQ   SEQUENCE   540 AA;  58702 MW;  EEA40123DB5233B4 CRC64;
     MARKQNRNSK ELGLVPLTDD TSHAGPPGPG RALLECDHLR SGVPGGRRRK DWSCSLLVAS
     LAGAFGSSFL YGYNLSVVNA PTPYIKAFYN ESWERRHGRP IDPDTLTLLW SVTVSIFAIG
     GLVGTLIVKM IGKVLGRKHT LLANNGFAIS AALLMACSLQ AGAFEMLIVG RFIMGIDGGV
     ALSVLPMYLS EISPKEIRGS LGQVTAIFIC IGVFTGQLLG LPELLGKEST WPYLFGVIVV
     PAVVQLLSLP FLPDSPRYLL LEKHNEARAV KAFQTFLGKA DVSQEVEEVL AESRVQRSIR
     LVSVLELLRA PYVRWQVVTV IVTMACYQLC GLNAIWFYTN SIFGKAGIPP AKIPYVTLST
     GGIETLAAVF SGLVIEHLGR RPLLIGGFGL MGLFFGTLTI TLTLQDHAPW VPYLSIVGIL
     AIIASFCSGP GGIPFILTGE FFQQSQRPAA FIIAGTVNWL SNFAVGLLFP FIQKSLDTYC
     FLVFATICIT GAIYLYFVLP ETKNRTYAEI SQAFSKRNKA YPPEEKIDSA VTDGKINGRP
//
